BC
RXRX icon

Barrett & Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Barrett & Company’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330 Buy
+90
New +$300 ﹤0.01% 692

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barrett & Company's RXRX Position: Q2 2026 in Review

Barrett & Company opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 90 shares worth $330. The stake represents ﹤0.01% of the portfolio and ranks #692 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Barrett & Company held 90 shares of Recursion Pharmaceuticals worth $330 as of Q2 2026.
  • Recursion Pharmaceuticals was a new Barrett & Company position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Barrett & Company's portfolio in Q2 2026, its #692 holding.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.